Dr Michaela Kotrova speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting the poster she was presenting on acute lymphoblastic leukaemia patients who were treated with CD19-directed immunotherapies.
She explains that by identifying somatic mutations acquired at the time of CD19-negative relapse in patients after blinatumomab treatment, they found CD19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell treatment.
Dr Kotrova explains the next steps to investigating this finding further and the importance of understanding the mechanism of CD-19 loss.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.